This topic takes on average 55 minutes to read.
There are a number of interactive features in this resource:
Animations: This topic has features with which you can interact, these are usually animations. Most of the animations can be expanded to full screen size, on a new window, ideal for showing on an interactive whiteboard. The animations will play all the way through or can be viewed one section at a time.
The biopharmaceutical industry is constantly developing new medicines. Pharmaceutical companies invest around £11m a day in Research and Development (R&D). R&D spending by the UK pharmaceutical industry is much higher than that of other industries.
Teams of chemists, pharmacologists and biologists search for molecules with medicinal properties. Molecular structures are altered to optimise activity and minimise unwanted side effects.
A technique called high-throughput screening has automated many of the initial tests and pharmaceutical laboratories may now screen thousands of compounds per week. Research chemists can use computers to model designer molecules and using the latest equipment, large pharmaceutical companies may synthesise and screen 300,000 molecules a year.
At this pre-clinical development phase, additional tests are carried out. These include animal tests to check that the chemical compound is not poisonous and chemical tests to show that it is stable enough to be used as a medicine. Promising medicines then pass on to the clinical development phase.
Robots used for screening compounds
For every new medicine that passes all the trials over 5,000 compounds need to be screened. On average It takes an amazing eleven years of development and, in 2014, cost £1.15 billion for each new medicine that reaches the patient. In 2016 there were over 7000 medicines in development to treat diseases such as cancer, diabetes and infectious diseases.
Find out about the different ways of delivering a medicine through this animation.